

<b>Title: Pasteurized Human Donor Milk (PDHM)</b>	<b>Division: Medical Management</b>
<b>Approval Date: 3/30/18</b>	<b>Department: Utilization Management</b>
<b>Effective Date: 3/30/18</b>	<b>LOB: Medicaid, Medicare, FIDA, HIV SNP, CHP, MetroPlus Gold, Goldcare I&amp;II, Market Plus, Essential, HARP</b>
<b>Review Date: 3/30/19</b>	<b>Policy Number: UM-MP229</b>
<b>Retired Date:</b>	<b>Cross Reference Number:</b>
	<b>Page 1 of 5</b>

## 1. POLICY:

Pasteurized Donor Human Milk (PDHM)

## 2. RESPONSIBLE PARTIES:

Medical Management Administration, Utilization Management, Integrated Care Management, Claims Department, Provider Contracting

## 3. DEFINITIONS:

Effective July 1, 2017, in accordance with the 2017-18 enacted state budget, pasteurized donor human milk (PDHM) for inpatient use is a covered benefit under the Medicaid program.

In accordance with an amendment to subdivision 2 of section 365-a of the Social Services Law, inpatient use of pasteurized donor human milk (PDHM), with fortifiers as medically indicated, requires a written medical order from a licensed medical practitioner.

## 4. PROCEDURE:

Medically necessary PDHM is covered for infants who:

- Have a documented birth weight of less than 1500 grams; or
- Have a congenital or acquired condition that places the infant at a high risk of developing necrotizing enterocolitis (NEC) and/or infection; or
- Have other qualifying condition(s) as determined by the Commissioner of Health or his/her designee.

Coverage of PDHM is for infants who meet the criteria outlined above and one or more of the following conditions:

- Are medically or physically unable to receive maternal breast milk or participate in breast feeding; or
- Are unable to participate in breast feeding despite optimal lactation support; or
- Are born to mothers whose breast milk isn't suitable for consumption due to the presence of certain substances or disease; or
- In cases where the mother is medically or physically unable to produce maternal breast milk at all or insufficient quantities.

<b>Title: Pasteurized Human Donor Milk (PDHM)</b>	<b>Division: Medical Management</b>
<b>Approval Date: 3/30/18</b>	<b>Department: Utilization Management</b>
<b>Effective Date: 3/30/18</b>	<b>LOB: Medicaid, Medicare, FIDA, HIV SNP, CHP, MetroPlus Gold, Goldcare I&amp;II, Market Plus, Essential, HARP</b>
<b>Review Date: 3/30/19</b>	<b>Policy Number: UM-MP229</b>
<b>Retired Date:</b>	<b>Cross Reference Number:</b>
	<b>Page 2 of 5</b>

### Limitations/Exclusions

- NYS tissue banking regulations require that PDHM be distributed only by tissue banks licensed by the NYS Department of Health and only with a written medical order. Of note, in order to provide medically fragile infants PDHM, a hospital must first have a tissue bank license from the NYS Department of Health that includes human milk. Information on how to obtain such license is available at: <https://www.wadsworth.org/regulatory/tissue-resources>
- Hospitals licensed to provide PDHM are required to bill using HCPCS code T2101
- Authorization is required

### 5. BACKGROUND:

New York’s Medicaid program will begin reimbursing hospitals outside the inpatient rate for pasteurized donor human milk (PDHM). Reimbursement went into effect on December 1 for Medicaid fee-for-service (FFS) and is effective on February 15, 2018, for Medicaid managed care (MMC) plans. PDHM coverage is only available for infants with a birth weight of under 1,500 grams or a condition that places them at high risk for developing necrotizing enterocolitis and/or an infection, and where maternal breast milk or breast feeding is not possible. To provide PDHM, hospitals must have a tissue bank license that includes human milk. Hospitals can bill and be paid for PDHM at the actual acquisition cost for Medicaid FFS patients. MMC plans must also cover PDHM, but billing and payment procedures are determined by individual plans. Hospitals should check with the plans for billing and payment information.

### 6. REFERENCES:

[https://www.health.ny.gov/health\\_care/medicaid/program/update/2017/jul17\\_mu.pdf](https://www.health.ny.gov/health_care/medicaid/program/update/2017/jul17_mu.pdf)

<https://www.gnyha.org/news/medicaid-to-pay-for-pasteurized-donor-human-milk/>

### 7. ATTACHMENTS:

	Title	Attachment
1		
2		
3		

### 8. REVISION LOG:



## Policy and Procedure

<b>Title: Pasteurized Human Donor Milk (PDHM)</b>	<b>Division: Medical Management</b>
<b>Approval Date: 3/30/18</b>	<b>Department: Utilization Management</b>
<b>Effective Date: 3/30/18</b>	<b>LOB: Medicaid, Medicare, FIDA, HIV SNP, CHP, MetroPlus Gold, Goldcare I&amp;II, Market Plus, Essential, HARP</b>
<b>Review Date: 3/30/19</b>	<b>Policy Number: UM-MP229</b>
<b>Retired Date:</b>	<b>Cross Reference Number:</b>
	<b>Page 3 of 5</b>

REVISIONS	DATE



## Policy and Procedure

<b>Title: Pasteurized Human Donor Milk (PDHM)</b>	<b>Division: Medical Management</b> <b>Department: Utilization Management</b>
<b>Approval Date: 3/30/18</b>	<b>LOB: Medicaid, Medicare, FIDA, HIV SNP, CHP, MetroPlus Gold, Goldcare I&amp;II, Market Plus, Essential, HARP</b>
<b>Effective Date: 3/30/18</b>	<b>Policy Number: UM-MP229</b>
<b>Review Date: 3/30/19</b>	<b>Cross Reference Number:</b>
<b>Retired Date:</b>	<b>Page 4 of 5</b>

<b>Approved:</b>	<b>Date:</b>	<b>Approved:</b>	<b>Date:</b>
Sosler Bruce, MD Clinical Medical Director		Talya Schwartz, MD Chief Medical Officer	

<b>Title: Pasteurized Human Donor Milk (PDHM)</b>	<b>Division: Medical Management</b>
<b>Approval Date: 3/30/18</b>	<b>Department: Utilization Management</b>
<b>Effective Date: 3/30/18</b>	<b>LOB: Medicaid, Medicare, FIDA, HIV SNP, CHP, MetroPlus Gold, Goldcare I&amp;II, Market Plus, Essential, HARP</b>
<b>Review Date: 3/30/19</b>	<b>Policy Number: UM-MP229</b>
<b>Retired Date:</b>	<b>Cross Reference Number:</b>
	<b>Page 5 of 5</b>

### Medical Guideline Disclaimer:

Property of Metro Plus Health Plan. All rights reserved. The treating physician or primary care provider must submit MetroPlus Health Plan clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, Metroplus Health Plan will not be able to properly review the request for prior authorization. The clinical review criteria expressed in this policy reflects how MetroPlus Health Plan determines whether certain services or supplies are medically necessary. MetroPlus Health Plan established the clinical review criteria based upon a review of currently available clinical information(including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). MetroPlus Health Plan expressly reserves the right to revise these conclusions as clinical information changes, and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by MetroPlus Health Plan, as some programs exclude coverage for services or supplies that MetroPlus Health Plan considers medically necessary. If there is a discrepancy between this guidelines and a member's benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members.

All coding and website links are accurate at time of publication.

MetroPlus Health Plan has adopted the herein policy in providing management, administrative and other services to our members, related to health benefit plans offered by our organization.